Phase 3 Readout

RCUS: Phase 3 Topline: A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chem

Name: Phase 3 Topline: A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chem
Start: 2030-11-30
End: 2030-11-30

November 30, 2030 · quemliclustat. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: November 30, 2030
Company: Arcus Biosciences, Inc. (RCUS)
Drug: quemliclustat

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chem

November 30, 2030

RCUS overview →

Company: Arcus Biosciences, Inc. (RCUS)
Drug: quemliclustat
Indication: Metastatic Pancreatic Ductal Adenocarcinoma